235 results about "Bladder cancer" patented technology

The invention provides a nervous tissue identification method based on artificial intelligence, and relates to the technical field of medical intelligent detection. According to the nervous tissue identification method, nervous tissue region annotation is carried out on 452 HE-dyed section images of bladder cancer, pancreatic cancer and porta-bile duct cancer by using QuPath software. 70% is used as a training set, 10% is used as a verification set of a training process, and 20% is used as an independent test set to train the nnUnet model. The whole training process is combined with an active learning strategy to enhance the specificity of the model. By using the algorithm and the deep learning technology, the nerve peripheral infiltration in the pathology is accurately and quickly evaluated, the workload of manual identification is greatly reduced, and the diagnosis accuracy is improved. The machine identification of tumor peripheral nerve invasion has obvious practicability, importance, clinical diversity and actual clinical value, and shows that the deep learning technology improves the potential of tumor detection and diagnosis.

The invention discloses a bladder cancer muscular layer infiltration and prognosis prediction system based on deep learning imageomics, relates to the technical field of medical treatment and belongs to auxiliary diagnosis, and adopts an imageomics method and a deep learning model to extract imageomics features and deep learning features of CT images respectively; compared with the prior art, potential meaningful features in the CT image are extracted more comprehensively, the prediction accuracy can be further improved, meanwhile, the features are screened more strictly by using technologies such as intra-class correlation coefficient (ICC) analysis, t inspection, Pearson correlation coefficient, minimum absolute contraction and selection operator (LASSO), PCA dimension reduction and Cox regression, and verification is performed in a plurality of external medical centers. On one hand, the over-fitting risk of the model can be greatly reduced, on the other hand, the excellent generalization of the model is also proved, the use of the model is not excessively influenced by the medical environment and the CT acquisition instrument, and the error generated by the multi-center effect can be effectively solved.

This invention is directed to a method of diagnosing bladder cancer in dogs.

The invention belongs to the field of bladder cancer treatment, and particularly relates to a drug delivery system based on combination of a biodegradable magnesium alloy stent and a double-J tube. The system comprises a biodegradable magnesium alloy stent and a double-J tube, the surface of the biodegradable magnesium alloy stent is modified by a calcium phosphate coating to form a fine needle-shaped micro-nano structure, and the biodegradable magnesium alloy stent loads an anti-cancer drug oridonin. The biodegradable magnesium alloy stent loaded with oridonin is accurately attached to a tumor part by means of ultrasonic guidance, and the double-J tube and the biodegradable magnesium alloy stent are combined for use. According to the invention, the loading efficiency of the hydrophobic drug is improved through the modification of the micro-nano structure of the calcium phosphate coating, and the anti-tumor effect of the magnesium degradation product is cooperated, so that the problems of high frequency, high toxicity and poor compliance of traditional bladder cancer perfusion treatment and difficulty in delivery of Ori and other natural drugs are solved, and finally, accurate, long-acting and low-toxicity treatment of bladder cancer is realized.

The invention relates to preparation and application of copper-sulfur group nano hydrogel. The research successfully synthesizes a copper-sulfur group nano-composite system with higher stability, the nano-system is utilized to perform experimental verification in vivo and in vitro, the application of the nano-system in the field of bladder cancer treatment is explored, a new strategy is provided for dealing with the limitation of current bladder cancer treatment, the Cu2-xSe (at) PDA (at) BTZ nano-material is prepared by utilizing a one-pot method, and the application of the nano-system in the bladder cancer treatment field is expanded. The surface of Cu2-xSe is modified through PDA, Cu2-xSe is wrapped in the PDA, bortezomib (BTZ) can be connected with the PDA through a phenylboronic acid ester bond, meanwhile, PDA of a coating layer of the composite material can be crosslinked with four-arm-polyethylene glycol-sulfydryl (4ARM-PEG-SH) to form nano hydrogel, the residence time of a medicine in the bladder can be prolonged through a copper-sulfur group nano-composite nano material, and the medicine can be applied to the bladder treatment. The contact time of the bladder mucosa and the medicine is prolonged, the medicine slow release effect is achieved, and efficient utilization of the medicine is achieved.

The invention provides an organoid chip for screening micro-ecological drugs as well as application and a preparation method of the organoid chip, and relates to the technical field of biological medicines. The invention provides a chip integrating intestinal epithelium, a prostate cancer organ and a bladder cancer organ, which is used for researching how microecological preparations, such as probiotics, metabolites and the like, affect tumor microenvironment and immunotherapy effects. The chip can simulate interaction of intestinal tract-tumor axis, and provides an in-vitro evaluation system for precise tumor immunotherapy.

The invention relates to a photodynamic therapy system for treating bladder cancer, and belongs to the technical field of photodynamic therapy. The system comprises a treatment catheter assembly used for performing laser energy delivery and biosensing signal acquisition on a bladder lesion area; the central control unit is used for data processing and control signal generation, and the central control unit can obtain tissue oxygen partial pressure and singlet oxygen concentration according to the biosensing signals collected by the treatment catheter assembly and generate control signals used for regulating and controlling laser energy delivery operation of the treatment catheter assembly according to the tissue oxygen partial pressure and the singlet oxygen concentration; the treatment catheter assembly can perform laser energy delivery operation on tumor tissue in a bladder lesion area in an intermittent mode, the interval time length and applied illumination parameters are changed based on the real-time concentration change condition of singlet oxygen, and the illumination parameters comprise light intensity and wavelength.

The invention discloses an engineered artificial vesicle and application of the engineered artificial vesicle in multiple in-situ detection of urine exosome miRNA, and belongs to the field of biosensors. The method comprises the following steps: constructing planar framework nucleic acid simultaneously modified with cholesterol and an aptamer through annealing reaction; a molecular beacon with a fluorophore is designed according to a target gene sequence, and the molecular beacon and a double-strand specific nuclease (DSN) system are jointly encapsulated in an artificial vesicle; the engineered artificial vesicles and a sample to be detected are incubated, the fluorescence modified molecular beacons can specifically recognize target genes, cyclic cutting and signal amplification are achieved under DSN mediation, and the broken molecular beacons release fluorescence signals; all fluorescence signals in the vesicles are collected through a fluorescence imaging technology, and a characteristic fluorescence spectrum of the to-be-detected sample is obtained. According to the present invention, the miRNA heterogeneity analysis at the single vesicle level and the precise multi-target detection of bladder cancer and other diseases can be achieved, and the problems of low throughput, target number limitation and the like of the existing vesicle in-situ detection are effectively overcome.

The invention provides a bladder cancer gene mutation prediction system based on deep learning, and the system comprises a histopathologic image collection module which is used for collecting an original to-be-detected histopathologic image; the preprocessing module is used for preprocessing the original to-be-detected histopathologic image by adopting an HE staining method and a full-slide imaging scanner to obtain WSI with HE stained bladder tissue; the cloud server module is used for calling a bladder cancer deep learning prediction model to perform bladder cancer gene expression state prediction, bladder cancer gene methylation state prediction and bladder cancer gene mutation state prediction on the WSI to generate corresponding prediction results; and the report generation module is used for automatically generating a bladder cancer gene mutation prediction auxiliary diagnosis report according to the corresponding prediction result and feeding back the report to the specified terminal.

The invention relates to a urine metabolism combined marker for diagnosing bladder cancer and a screening method of the urine metabolism combined marker. The urine metabolism combined marker is prepared from 2-methyl furan, dimethyl disulfide, octylene and acetophenone. The method for screening the urine metabolism combined marker comprises the following steps: carrying out chromatographic separation and mass spectrometry detection on a urine sample on the basis of a headspace automatic sampler in combination with a chromatographic column and a photochemical ionization time-of-flight mass spectrometry, preprocessing mass spectrometry data, and extracting spectrum peak data of metabolites in urine; the urine metabolism combination marker for diagnosing bladder cancer is obtained through further statistical analysis. The screening method of the urine metabolism combined marker for diagnosing the bladder cancer has the advantages of non-invasiveness, high-throughput detection, simplicity in operation and accurate result, and has a wide application prospect.

Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and / or proteins associated with neurological diseases and / or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and / or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.

The invention relates to the field of organic chemistry and medicinal chemistry, in particular to an indeno-aza compound I as well as a preparation method and medical application thereof. The method comprises the following steps: adding an amine compound into an indeno-oxa-heptacyclic compound serving as a raw material under solvent-free and additive-free conditions, directly adding stoichiometric thionyl chloride and a solvent acetonitrile into an intermediate product obtained after the reaction without separation and pretreatment to continue the reaction, adding alkali again without separation and pretreatment after the reaction is completed, and separating and purifying to obtain the product. And controlling the reaction temperature to finally prepare the indeno-aza compound. The invention reports a compound with a novel structure, and develops a one-pot continuous operation synthesis method of the compound. The synthesis operation of the method conforms to the concept of green chemistry, and the obvious advantages of chemical synthesis means are embodied. Meanwhile, the compound has a certain inhibition effect on human esophageal cancer cells and human bladder cancer cells.

The invention discloses a Nectin-4 targeted nucleic acid aptamer nuclide diagnosis and treatment integrated probe, and relates to the field of biotechnology and diagnosis and treatment integration and treatment, and the diagnosis and treatment integrated probe comprises a Nectin-4 targeted nucleic acid aptamer, a nuclide chelating ligand and a nuclide for marking; wherein the Nectin-4 targeting nucleic acid aptamer has a base sequence as shown in any one of SEQ ID NO.1-3, or has a base sequence of which the homology with the base sequence as shown in any one of SEQ ID NO.1-3 is more than 80%. The diagnosis and treatment integrated probe prepared by the invention can be applied to PET / CT diagnosis and internal irradiation radioactive therapy, on one hand, non-invasive visual molecular imaging of Nectin-4 receptor protein overexpression tumors is realized, and on the other hand, radioactive therapy of malignant bladder cancer is further realized; the probe is good in specific targeting effect and high in tumor uptake and has a diagnosis and treatment integrated function.

The invention provides an application of CCPG1 as a molecular marker in preparation of a product for diagnosis or prognosis of bladder cancer, and it is found for the first time that the CCPG1 gene has significant high expression in bladder cancer and can be used for early diagnosis of bladder cancer; and the highly expressed CCPG1 gene is closely related to poor prognosis of bladder cancer, which prompts that the CCPG1 gene can be used as a prognosis marker, and provides effective information for early diagnosis, prognosis evaluation and treatment effect monitoring of bladder cancer. The expression level of CCPG1 in tissue of a patient can be detected, so that a cystacarcinoma patient and a normal control person can be quickly and conveniently distinguished, the sensitivity reaches 85% or above, and the specificity reaches 70% or above.

The present disclosure relates to a method for treating triple-negative breast cancer or non-muscle-invasive bladder cancer in a subject, comprising administering to the subject a composition comprising nonviable cells of Streptococcus pyogenes and an immune checkpoint inhibitor.

A method for treating bladder cancer is provided at this institution.

The invention discloses a bladder cancer mutation detection and typing method and system using pathomics characteristics, and relates to the technical field of disease detection.The bladder cancer mutation detection and typing method comprises the steps that related data of bladder cancer tissue of a patient is received, and then a bladder cancer tissue pathological section image is subjected to image segmentation to obtain a segmented bladder cancer tissue pathological section image; feature extraction processing is carried out based on the segmented bladder cancer tissue pathological section image to obtain bladder cancer tissue pathological feature data, feature weight weighting processing is carried out based on the bladder cancer tissue pathological feature data to obtain a bladder cancer comprehensive weight coefficient, and the bladder cancer comprehensive weight coefficient is predicted through an ecDNA probability prediction model to obtain an ecDNA probability coefficient; and performing multi-modal space fusion on the ecDNA probability coefficient and bladder cancer tissue gene data to obtain an ecDNA risk score, and finally realizing bladder cancer mutation detection and typing based on the ecDNA risk score.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

The application provides a urine exosome-based bladder cancer gene detection system and application, and relates to the technical field of biological detection. Through the cooperative application of the internal reference gene and the diagnosis model, the application provides a reliable endogenous quality control standard for the bladder tissue-derived exosome in the urine exosome sample; meanwhile, the application realizes non-invasive, accurate, rapid screening, diagnosis, prognosis and recurrence monitoring of bladder cancer, lays a key technical foundation and detection tool for the urine exosome-based molecular diagnosis of bladder cancer, and has important clinical transformation value and application prospect.

The invention provides a human FGFR3 (Fibroblast Growth Factor Receptor 3) antigen expression recombinant yeast vaccine as well as a construction method and application thereof. A specific primer is designed to amplify an FGFR3 gene, a pEGKT316-FGFR3 recombinant plasmid is constructed, a saccharomyces cerevisiae YEF473A strain is transformed, and the vaccine is prepared through induced expression and thermal inactivation. The vaccine can effectively activate DC cell maturation (CD80 + cell proportion reaches 78.7%) and promote Th1 type cell factor secretion (IL-12p70 reaches 5889pg / mL), and shows a remarkable tumor inhibition effect (plt; 0.05), and a novel specific treatment means is provided for postoperative immunotherapy of bladder cancer.

The application finds that SDF4 in a body fluid sample can become a marker for detecting cancer patients with good sensitivity and specificity. By using a reagent for specifically detecting SDF4, gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected. The measurement of SDF4 in a body fluid sample is a detection method capable of detecting various cancers by a single test, and can be used for large-scale screening of cancers. In addition, early-stage cancers can be detected with good sensitivity and specificity, so that cancers can be found and treated in an early stage.

The present invention relates to the treatment of locally advanced and metastatic muscle-invasive bladder cancers (MIBC). The present invention provides compositions to be used in immunotherapy of MIBC, especially in combination with an anti-PD-1 / PD-L1 / PD-L2 antibody-based therapy. The present invention also provides biomarkers of response to anti-PD-1 / PD-L1 / PD-L2 immune checkpoint blocking antibodies (ICBs), alone or together with anti-CTLA4 antibodies and / or chemotherapy, for best guiding their neoadjuvant use and avoid unefficient administration of potentially toxic drugs to patients with localized bladder cancers.

Provided herein are methods of treatment, erdafitinib for use and use of erdafitinib for the treatment of bladder cancer harboring one or more FGFR alterations comprising locally delivering erdafitinib into the bladder of a patient.

The invention discloses application of cinnabine in antitumor drugs and a drug, the molecular formula of the cinnabine is C14H10N2O5, and tumors comprise at least one of colorectal cancer, pancreatic cancer, lung cancer, liver cancer, gastric cancer, thyroid cancer, kidney cancer, bladder cancer, ovarian cancer, cervical cancer, breast cancer, myeloma, hemangioma and central nervous system tumor. The anti-tumor mechanism of the cinnabarine is to inhibit a KRAS G12D mutation subtype. The cinnabaric acid can effectively inhibit proliferation of various tumor cells, and is expected to be applied to tumor treatment as an anti-tumor small-molecular targeted drug.

The invention discloses a gemcitabine drug sensitive marker, a detection kit and application of the gemcitabine drug sensitive marker, the gemcitabine drug sensitive marker is a gemcitabine drug-resistant marker or / and a gemcitabine sensitive marker, and the gemcitabine drug-resistant marker is one or more of ATOH8, DAPK2, BCL2L2, PNPLA2, SHROOM1, FGGY, CPQ, CPO, SLC10A5, ADAMTS15, COL25A1, ASMTL and ENSG00000286264; the sensitive marker is one or more of FAM163A, KREMEN2, VPS37D, GGCT (Growth Growth Computed Tomography), ADSL (Asymmetrical Digital Subscriber Loop), FOXL2 (Focal OXL2), MAST1 (MAST1), DNAAF3 (Deoxyribose Nucleic Acid Amplified The gemcitabine drug sensitive marker is used for predicting the drug effect of gemcitabine. According to the present invention, the expression of the related molecules is detected through the sequencing of the tissue transcriptome of the urothelial carcinoma patient, or through the PCR, the gene chip, the tissue chip, the NanoString technology, the immunohistochemistry and the ELISA method, and the guidance is provided for the drug use of gemcitabine and the precise treatment of bladder cancer.

The present invention refers to the use of recombinant Mycobacterium strains encoding the A subunit of the heat-labile LT toxin from mutated Escherichia coli, in the manufacture of an immunobiological composition for the prevention and / or treatment of cancer in animals. Preferably, the mutation is at position 63 from serine to lysine. The present invention also provides immunobiological compositions comprising said strains for use in the prevention and / or treatment of cancer. At last, the present invention refers to methods for the prevention and / or treatment of cancer, comprising the administration of said strains to a subject in need thereof. In particular, said cancer is bladder cancer.

Provided are a method and kit for measuring the methylation levels of bladder cancer biomarkers. The bladder cancer biomarkers include a Twist1 gene and an SPN gene. By means of measuring the methylation levels of the Twist1 gene and the SPN gene, the present application can accurately detect bladder cancer.

It has been found that SDF4 in a body fluid sample can be a marker for detecting a cancer patient with good sensitivity and specificity. Gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, hepatic cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected by using a reagent that specifically detects the SDF4. The measurement of the SDF4 in the body fluid sample is an examination method capable of detecting various types of cancer with a single examination, and can be used for mass screening for cancer. Moreover, early-stage cancer can also be detected with good sensitivity and specificity, and thus cancer can be discovered at an early stage, leading to treatment.

Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting a set of markers consisting of CRH, IGF2, KRT20, and ANXA10.